Gilead and Merck announce positive Phase 2 data for weekly oral HIV combination regimen of islatravir and lenacapavir.

Gilead Sciences and Merck & Co. announced positive Phase 2 data on a weekly oral HIV combination regimen, consisting of Merck's islatravir and Gilead's lenacapavir, which maintained viral suppression. This combination therapy has the potential to be the first weekly oral HIV treatment.